Exhibit 10.2


 


INTELLECTUAL
PROPERTY LICENSE AGREEMENT


 


This
Intellectual Property License Agreement (“Agreement”) is made, entered into, and effective as of April 2, 2021 (the
“Effective Date”) by and between Medovex Corp., a Nevada corporation having an address at 201 E. Kennedy Blvd,
Suite 700, Tampa, Florida 33602 (“Licensor”) and Medovex, LLC, a Delaware limited liability company (“Licensee”).


 


Background


 


Medovex
owns certain personal property that the Licensee believes would be useful for or in the conduct of its business. The parties have entered
into that certain Contribution Agreement of even date herewith that contemplates a transaction in which Medovex will assign and contribute
such personal property and related rights, constituting all of the tangible assets of Medovex relating to the DenerveX® rotational
ablation denervation device (the “DenerveX Device”) to the Licensee in exchange for the Consideration described in
the Contribution Agreement. The contributed assets exclude all Intellectual Property (defined below) in or to the DenerveX Device, and
Licensor retains ownership of all such Intellectual Property. Licensee would like to license the Intellectual Property for use in commercializing
the DenerveX Device, and Medovex is willing to grant such a license to Licensee subject to the terms and conditions of this Agreement.


 


Now
therefore, in consideration of the mutual promises and benefits stated herein, the receipt and sufficiency of which consideration is
hereby acknowledged, the parties, intending to be legally bound, agree as follows:


 


ARTICLE
1 – DEFINITIONS


 


1.1.
“Base Applications” means the pending patent applications identified in Exhibit “A,” attached hereto and
incorporated herein by this reference. The term “Base Applications” also includes all divisionals, continuations, reissues,
re-examinations, continuation-in-part applications, and any other applications claiming priority to or the benefit of any of the Base
Applications or any applications from which any Patent issues or grants.


 


1.2.
“Improvements” means all inventions, developments, modifications, or improvements of an invention, component, method,
process, material, or design, whether or not patentable, relating to the Patents, Base Applications, Technology, Intellectual Property,
or Licensed Product that are made or acquired by Licensor or Licensee during the Term of this Agreement.


 


1.3.
“Intellectual Property” means all intellectual property rights in or to the DenerveX Device, including, without limitation:
(i) all Patents and Base Applications; (ii) the Technology and all other inventions (whether patentable or not in any country), invention
disclosures, trade secrets, proprietary information, know-how, technical data, and claimed and unclaimed subject matter disclosed in
any of the Patents or Base Applications; (iii) copyrights, mask works, copyright registrations, mask work registrations, and applications
therefor in any country, and all other rights corresponding thereto throughout the world; (iv) the Trademarks; (v) other proprietary
rights in technology, including, without limitation, design history files, sterilization plans, specifications, recipes of systems and
subsystems, data, reports and records, software (in source code and object code), algorithms, architecture, databases, development tools,
and all documentation and media constituting, describing, or relating to the above, including, without limitation, manuals, memoranda,
business information, anywhere in the world, and all updates, upgrades, corrections, modifications, translations, releases, versions,
and derivative works and improvements of each of the foregoing items; (vi) Improvements to any of the foregoing; and (vii) any applications,
registrations, provisional applications, or other filings for, or to obtain, protect, perfect, or secure any of the foregoing, anywhere
in the world.


 




    	 



     


    

 


1.4.
“Key Patent Nonenforceability Event” means if at any time during the Term, one or more of the patents identified on
Exhibit “B” to this Agreement become invalid or unenforceable in courts of competent jurisdiction within the European Union
and all appeals and opportunities for appeals are finally exhausted, and Licensor does not cure such occurrence within sixty (60) days
of its receipt of notice thereof of such invalidity or unenforceability.


 


1.5.
“Licensed Field” means all uses in all areas, both commercial and non-commercial, without any exclusions or exceptions.


 


1.6.
“Licensed Product” means, collectively, the DenerveX Device and any other article, device, method, process, or activity
exploited by Licensee, including, without limitation, any making, using, selling, importing, and offering for sale that (i) would otherwise
infringe any one or more claims of any Patent in the absence of a right or license; or (ii) uses, incorporates, or otherwise employs,
in whole or in part, any Intellectual Property other than the Patents.


 


1.7.
“Gross Sales” means the total revenues derived by Licensee from the sale of the Licensed Product without deductions
or set-offs of any kind or nature.


 


1.8.
“Patent” means the patents identified in Exhibit “A,” any and all patents issuing during the Term within
the Territory claiming priority to or the benefit of any one or more of the Base Applications.


 


1.9.
“Royalties” means, collectively, all Patent Royalties and all IP Royalties, which terms are defined in Sections 3.1(b)
and 3.1(c) below, respectively.


 


1.10.
“Sale of the Company” means (a) the closing of the sale, transfer or other disposition, in a single transaction or
series of related transactions, or all or substantially all of Licensee’s assets or (b) a transaction or series of related transactions
in which a person or entity, or a group of related persons or entities, acquires from the equityholders of Licensee’s securities
representing more than fifty percent (50%) of the outstanding voting power of Licensee. For the avoidance of doubt, a transaction will
not constitute a “Sale of the Company” if its sole purpose is to change the state of Licensee’s formation or to create
a holding company that will be owned in substantially the same proportions by the persons who held Licensee’s securities immediately
prior to such transaction.


 


1.11.
“Technology” means all trade secrets, and all other data, discoveries, inventions, technical information, manufacturing
processes, and know-how that are not publicly or generally known and that are disclosed to Licensee by or on behalf of Licensor under
this Agreement for the use in the commercialization of the DenerveX Device.


 


1.12.
“Term” means the term of this Agreement as set forth in Section 9.1 below.


 




    	2



     


    

 


1.13.
“Territory” means worldwide.


 


1.14.
“Trademarks” means all of Licensor’s trademarks related to the DenerveX Device, whether registered or unregistered,
including, without limitation, the trademarks identified in Exhibit “A,” and all similar trademarks, service marks, trade
dress, trade names, logos, internet domain names, and registrations and applications for registration thereof, together with all of the
goodwill associated therewith.


 


ARTICLE
2 - GRANT OF LICENSE


 


2.1.
Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, personal, non-transferable,
limited license to make, use, sell, offer for sale and import the Licensed Products in the Licensed Field and throughout the Territory
using the Intellectual Property during the Term (hereinafter the “License”). Licensee shall not have the right to
grant sublicenses, without the express permission of the Licensor. Any rights not expressly granted to Licensee in this Agreement are
retained by and reserved to Licensor.


 


ARTICLE
3 - PAYMENTS UNDER THE LICENSE


 


3.1.
Royalties. Licensee agrees to pay to Licensor the following royalties:


 


3.1.1.
During the Patent Royalty Period (defined below), a royalty of six percent (6%) of the Gross Sales of all Licensed Products sold by Licensee
in the Licensed Field within the Territory (the “Patent Royalties”), provided, however, that the Licensee’s
first $666,666.67 of Gross Sales shall be exempt from the Patent Royalties; and


 


3.1.2.
Upon expiration of the Patent Royalty Period and for the remainder of the Term, a royalty of two percent (2%) of the Gross Sales of all
Licensed Products sold by Licensee in the Licensed Field within the Territory after the Term (the “IP Royalties”).


 


3.2.
Patent and IP Royalties. Licensee acknowledges and agrees that it is paying two separate and independent Royalties (Patent Royalties
and IP Royalties) under this Agreement for activities relating to the Licensed Product.


 


3.3.
Payment of Royalty. Royalties will be computed quarterly on a calendar year basis. Beginning on the Effective Date, the Royalties
will begin to accrue immediately and will be paid quarterly based upon the following schedule:


 


3.3.1.
For the period of January 1st through and including March 31st, payment shall be due on or before April 15th;


 


3.3.2.
For the period of April 1st through and including June 30th, payment shall be due on or before July 15th;


 


3.3.3.
For the period of July 1st through and including September 30th, payment shall be due on or before October 15th; and,


 


3.3.4.
For the period of October 1st through and including December 31st, payment shall be due on or before January 15th of the following year.


 




    	3



     


    

 


For
purposes of this Section, the term “Royalty Year” shall mean each consecutive twelve (12) month period beginning on
the Effective Date and ending on the anniversary of the Effective Date.


 


3.4.
Patent Prosecution and Maintenance Fees. Beginning on the Effective Date and continuing until the end of the Patent Royalty Period,
Licensee shall be responsible for all costs, fees, expenses, and amounts, including, without limitation, all maintenance fees, annuities,
and attorneys’ fees, incurred by Licensor for the prosecution and maintenance of the Patents and Base Applications in all jurisdictions
throughout the Territory.


 


3.5.
Unpaid Amounts. Any payments not timely made under this Agreement and any underpayments of previously owed amounts shall bear
interest from the time such payment was due at the rate of one and one-half percent (1.5%) per month or the highest rate permissible
by law if less.


 


3.6.
Currency. Royalty payments will be made in U.S. Dollars regardless of where the Licensed Product is made or sold and notwithstanding
currency restrictions or regulations in any country where the Licensed Product is sold. Sales made in any currency other than U.S. Dollars
will be converted at the applicable rate of exchange published in the Wall Street Journal on the last day of the accounting period
in which the Royalty payments accrue. Each such payment will include the Royalties which have accrued during the calendar quarter immediately
preceding.


 


3.7.
Royalty Period.


 


3.7.1.
Patent Royalty Period. Licensee’s obligation to pay Patent Royalties shall commence upon the Effective Date and shall continue
until the earlier of (i) termination or expiration of this Agreement; (ii) the fifteen (15) year anniversary of this Agreement; and (iii)
upon the occurrence of a Key Patent Nonenforceability Event, the later of (A) the date of such Key Patent Nonenforceability Event and
(B) the five (5) year anniversary of this Agreement (“Patent Royalty Period”). Notwithstanding the foregoing, if a
Sale of the Company occurs following the occurrence of a Key Patent Nonenforceability Event, the Patent Royalty Period shall be deemed
to have expired upon the closing of such Sale of the Company event. All such Patent Royalties shall be paid during the full Patent Royalty
Period in the manner set forth in this Article 3.


 


3.8.
Taxes. In addition to the charges due under this Agreement, and even if Licensee shall provide a tax exemption number or affidavit
of exemption or other evidence of exemption, the Licensee shall be responsible for and reimburse Licensor for any taxes, including without
limitation, sales, use, property, excise, VAT, value added and gross receipts levied on this Agreement, any payments hereunder and any
activities subject to the License, except for taxes based solely on Licensor’s income (“Tax”). If necessary
this Tax, when being collected, shall be paid by Licensee in the name of Licensor. Licensee shall not withhold any Tax or other amounts
from any Royalties or other payments owing to Licensor under this Agreement.


 


ARTICLE
4 – TRADEMARKS


 


4.1.
Trademark Use Approval. Licensor shall have the right to approve any products, services, advertisements, or other materials exhibiting
or otherwise using the Trademarks (the “Materials”). Licensor’s approval shall not be unreasonably withheld.
Such approval may be given orally or implied based upon a review of Materials by Licensor’s personnel working for Licensee without
objection or based upon Licensor’s participation in the design and creation of Materials. Any Materials submitted to Licensor shall
be deemed approved unless Licensor notifies Licensee to the contrary within thirty (30) days after receipt of such Materials. Any product
developed, manufactured, distributed, sold, and advertised by Licensee shall conform to the Materials approved or deemed approved by
Licensor. Licensor shall have the right to terminate the License and this Agreement upon Licensee’s failure to have any Materials
approved after having received written notice from Licensor of such failure and a reasonable opportunity to cure.


 




    	4



     


    

 


4.2.
Acknowledgment and Marking. Licensee acknowledges and agrees that: (i) Licensor is the sole and exclusive owner of all rights,
title, and interest in and to the Trademarks and of the right to use the Trademarks and to grant the Licenses for use of the Trademarks
by Licensee; (ii) Licensee will never claim or assert any claim of ownership or title to the Trademarks; (iii) Licensee will never claim
any right to use the Trademarks except for the License expressly granted by Licensor under this Agreement; and (iv) Licensor at all times
has retained ownership of the Trademarks and has made no transfers thereof to Licensee under any other agreement. Licensee shall prominently
display the Trademarks in connection with commercialization of the DenerveX Device and shall include all notices and legends with respect
to Licensor’s Trademarks as are or may be required by applicable federal, state, and local trademark law or which may be reasonably
requested by Licensor.


 


4.3.
Use of Similar Marks. Licensee shall at no time adopt or use, without Licensor’s prior written consent, any variation of
the Trademarks, including translations, or any mark likely to be similar to or confusing with the Trademarks. In the event that Licensor
consents to any variation of the Trademarks, Licensee herby agrees that Licensor shall own such new mark and Licensor shall have the
right to file and obtain in Licensor’s name all United States and international trademark registrations. Licensee agrees to give
Licensor reasonable assistance, including execution and delivery of all documents required by Licensee, in filing such applications for
trademark registration.


 


4.4.
Trademark Validity. Licensee shall not contest or deny the validity or enforceability of any or all of the Trademarks or oppose
or seek to cancel any registration thereof by Licensor, or aid or abet others in doing so, either during the Term of this Agreement or
at any time thereafter.


 


4.5.
Good Faith Business. Licensee agrees that it shall conduct its business in a dignified manner, consistent with and enhancing the
general reputation of the Trademarks and Licensor, and in accordance with good trademark practice.


 


4.6.
Goodwill. Any and all goodwill arising from Licensee’s use of the Trademarks and attributable to the Trademarks shall inure
solely to the benefit of Licensor, and neither during the Term or following the termination, cancellation or expiration of this Agreement
and the License granted hereunder shall Licensee assert any claim to the Trademarks or such goodwill. Licensee shall not take any action
that could be detrimental to the goodwill associated with the Trademarks or with Licensor.


 


ARTICLE
5 – RECORDS UNDER THE LICENSE


 


5.1.
Records and Accounting. During the Term of this Agreement and for seven (7) years thereafter, Licensee and shall keep complete
and accurate records of its Gross Sales under the License and all activities under this Agreement in sufficient detail to enable the
Royalties and other amounts payable hereunder to be determined and in accordance with generally accepted accounting principles. Licensee
agrees to permit Licensor and its accountants, agents, and other designees with five (5) business days written notice, to periodically
examine its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report
required under this Agreement and to conduct an audit (hereinafter referred to as the “Audit”). Licensor shall pay
its own costs associated with the Audit unless the Audit results reflect an underpayment by Licensee of five percent (5%) or more of
any payment due hereunder. In such instance Licensee shall pay all of Licensor’s costs and expenses associated with the Audit.


 




    	5



     


    

 


ARTICLE
6 - PATENT PROSECUTION AND ENFORCEMENT


 


6.1.
Filing and Prosecution of Patent Applications. The right to file, prosecute, and control all Patents, Base Applications, and other
Intellectual Property rights rests solely with the Licensor. Licensor, in its sole discretion, will control the decision to file and
the prosecution of all Patents and other Intellectual Property throughout the Territory.


 


6.2.
Patent and Trademark Maintenance and Renewal. Licensee shall have sole responsibility for all post-grant and post-issuance maintenance
of the Patents and Trademarks, including, without limitation, by timely paying all maintenance fees and annuities in each jurisdiction
where the Patents and Trademark subsist, and by timely filing all affidavits, evidence, and other documents for the purpose of maintaining
enforceability of the Patents and Trademarks throughout the full extent of the Term. Licensee acknowledges and agrees that this obligation
is undertaken as a reasonable allocation of expense to Licensee in its role under the exclusive License in the Territory. Licensee’s
discharge of this responsibility in no way shall be construed as transferring any ownership interest in or to the Patents or Trademarks
from Licensor to Licensee.


 


6.3.
Enforcement. Licensee has a duty to notify Licensor of any known and/or suspected infringement of the Licensed Product occurring
within the Territory. The right to institute such a suit for infringement of the Licensed Product occurring within the Territory rests
solely with the Licensee, provided that if Licensee fails to promptly institute such suit for infringement or informs the Licensor that
it does not plan to institute such suit for infringement, Licensor shall have the option, exercisable upon written notice to Licensee
to assume and control the institution of such suit. Licensee will provide full cooperation and assistance in any actions brought by Licensor,
including Licensee’s joining the suit as a party.


 


6.4.
Validity Challenges by Licensee.


 


6.4.1.
Licensee shall not institute or actively participate as an adverse party in, or otherwise provide material support to, any legal action
or administrative proceeding to obtain a ruling that any Patent claim is invalid, unenforceable, or not patentable or that any Licensed
Product does not infringe one or more claims of any Patent (“Patent Challenge”) until the expiration of sixty (60)
days after Licensee serves on Licensor written notice of such Licensee’s intention to bring or participate in a Patent Challenge.
Licensee shall also provide to Licensor a complete written disclosure of each and every basis then known to Licensee for the Patent Challenge
and shall provide Licensor with a copy of any document or publication that such Licensee may use in connection with the Patent Challenge.


 


6.4.2.
Upon the commencement of a Patent Challenge, (by the Licensee only) the Licensor, it its sole discretion, may either (i) immediately
terminate this Agreement; or (ii) immediately terminate the exclusivity of the license granted in Section 2.1 of this Agreement, and
Licensee’s continued exploitation of all Licensed Products thereafter shall be on a non-exclusive basis.


 




    	6



     


    

 


6.4.3.
Any Patent Challenge asserted by Licensee shall be brought solely and exclusively in the U.S. District Court for the Middle District
of Florida, Tampa Division, in Hillsborough County, Tampa, Florida. Licensee shall not file any Patent Challenge in the Patent Trial
and Appeal Board of the U.S. Patent & Trademark Office, or in any equivalent or counterpart administrative tribunal in any jurisdiction
in the Territory.


 


6.4.4.
Licensee’s failure to comply with the provisions of this Section 6.4 shall constitute a material breach of this Agreement.


 


ARTICLE
7 - WARRANTIES AND OBLIGATIONS OF LICENSEE


 


7.1.
Warranties to Licensor. Licensee represents and warrants to Licensor and each purchaser or customer of Licensed Products that:
(1) all services, manufacturing and other activities under the License and this Agreement shall be performed in a professional workmanlike
manner; (2) Licensee has good title to all Licensed Products sold or delivered hereunder, free and clear of all liens and encumbrances;
(3) Licensee shall use best efforts to ensure that all Licensed Products and related services and activities under the License are performed
and delivered free of material defects in manufacture, design, and workmanship; and (4) Licensee shall manufacture and use the Licensed
Products with the same quality as manufactured by the Licensor. Licensor shall have the right to control the agreed-upon quality and
to stop the sale of Licensed Products which are below standard. Licensor may exercise this right to control by personal inspection of
the production. The foregoing representations and warranties are material obligations placed upon Licensee.


 


7.2.
Indemnification. Notwithstanding any provision of this Agreement to the contrary, Licensee agrees to defend, hold harmless, and
indemnify Licensor, its officers, employees, and agents from and against any claims, loss, damage, injury demands, or causes of action
whatsoever (“Losses”) including, without limitation, those arising on account of: (i) any injury or death of persons
or damage to property of Licensor or any third party caused by, or arising out of, or relating to any intentional, reckless or negligent
act or omission; (ii) strict liability or product liability of Licensee or its employees, sub-licensees, agents, or invitees in performing
any and all obligations or services under this Agreement; (iii) Licensee’s manufacture, use, distribution, or sale of Licensed
Products, including, without limitation, the use thereof by any third party; (iv) any breach of this Agreement; or (v) Licensee’s
exercise or practice of the License granted hereunder; provided, however, that Licensee’s obligations under (i), (iii), and (iv)
above shall not apply to Losses occurring prior to the Effective Date.


 


7.3.
Marking. The Licensee shall comply with all patent marking requirements under all applicable laws within the Territory including,
without limitation, placing in a conspicuous location on all Licensed Products a patent notice in accordance with the United States patent
laws, including 35 U.S.C. § 287 and the laws of all other jurisdictions within the Territory. The Licensee agrees to mark any products
made using a process covered by a Patent with the number of each such Patent. 


 


7.4.
Compliance With Laws. Licensee shall comply at all times at its sole expense with all applicable state and federal laws, rules,
licensing and regulations pertaining to its business and operations and its performance of the Services including, without limitation,
compliance with all state and federal laws, and the laws of all other jurisdictions within the Territory.


 




    	7



     


    

 


7.5.
Trade Secrets. Licensee acknowledges and agrees that: (a) the Technology is comprised of trade secrets and confidential and proprietary
information that is not publicly or generally known, is not readily ascertainable by proper means, possesses substantial and significant
economic value by remaining secret, and has been the subject of reasonable efforts to maintain its secrecy; (b) the Technology cannot
be derived from the Base Applications; (c) Licensor is the sole and exclusive owner of the Technology; and (d) Licensee does not possess
the Technology or any related know how to implement a production process or to manufacture products that achieve the advantages of the
Technology. Licensee agrees that during the term of this Agreement and thereafter it shall not take any present or future direct or indirect
action to challenge, attack, or otherwise contest the validity, ownership, or rights of Licensor in or to the Technology’s status
as trade secrets protected from disclosure and use under all applicable laws, or to enjoin, oppose or otherwise interfere with Licensor’s
full enjoyment and use of the Technology as trade secrets in any manner whatsoever world-wide. Nor shall Licensee aid any third party
in connection with the foregoing. 


 


ARTICLE
8 - DEFENSE AND INSURANCE


 


8.1.
Defense. In the event a third party brings an action to obtain a declaration of invalidity of one or more Patents, (a “DJ-Action”)
against the Licensor and/or the Licensee, then the Licensor shall have the first right to defend said action at its own costs and expense
and to control the ensuing litigation. If the Licensor elects not to defend the DJ-Action, then Licensee may defend the DJ-Action at
its own cost and expense and to control the ensuing litigation. If a litigating party finally prevails, it shall retain all damages which
it may collect.


 


8.2.
Insurance. Licensee shall maintain Comprehensive General Liability and Property Damage Insurance (including completed operations
and product liability coverage) of not less than $2,000,000 per person, $2,000,000 per occurrence for bodily injury, and $1,000,000 per
occurrence for property damage as protection against all risks of damage to or destruction of property or bodily injury, sickness, or
disease (including death resulting at any time therefrom) of persons, wherever located, resulting from Licensee’s or its sub-licensee’s
negligence, strict liability, product liability, or failure to exercise reasonable care in performing the obligations hereunder in accordance
with applicable law. Licensor shall be named as an additional insured on all such policies, and Licensee shall provide Licensor with
evidence of the same in the form of an endorsement. All insurance coverage required hereunder shall be issued in a form reasonably acceptable
to Licensor. All insurance coverage procured hereunder shall provide that no material change or cancellation in insurance shall be made
by Licensee without thirty (30) days prior written notice to Licensor. Compliance or failure to comply by Licensee with the foregoing
requirements, as to carrying insurance and furnishing certificates, shall not relieve Licensee of its liabilities and obligations under
this section.


 


8.3.
Limitation on Liability. EXCEPT FOR CASES OF LIABILITY FOR INTENTION, IN NO EVENT SHALL LICENSOR BE LIABLE TO LICENSEE OR LICENSEE’S
SUCCESSORS, ASSIGNS, OFFICERS, DIRECTORS, EMPLOYEES, CONTRACTORS, OR AGENTS FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL DAMAGES, OR LOST
PROFITS, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR TO THE PERFORMANCE OR BREACH THEREOF, EVEN IF LICENSOR HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.


 




    	8



     


    

 


ARTICLE
9 - TERM OF LICENSE AND TERMINATION


 


9.1.
Term. Unless terminated in accordance with Section 9.2 or 9.3 below, the term of this Agreement shall begin on the Effective Date
and shall continue until Licensee ceases all commercial use or exploitation of the Licensed Products in the Territory (“Term”).


 


9.2.
Default by Licensee. Except as set forth in Section 9.3, Licensor has the right to terminate this Agreement and the License granted
to Licensee hereunder: (i) pursuant to Section 6.4.2, or (ii) if the Licensee at any time defaults in any material obligation under this
Agreement, and such default is not cured within sixty (60) days after written notice from Licensor to Licensee specifying the nature
of the default, and such termination will become effective at the close of business on the thirtieth day after giving such notice. For
purposes of this Section 9.2, it shall be a material breach of this Agreement by Licensee if Licensee becomes bankrupt or insolvent and/or
if the business of Licensee is placed in the hands of a receiver, assignee for the benefit of creditors, or trustee, whether by voluntary
act of Licensee or otherwise, and Licensor shall have the right to terminate if not cured by Licensee after Licensor has provided Licensee
with notice and sixty (60) days to cure as set forth above in Section 9.2(ii).


 


9.3.
Termination for Nonpayment. This Agreement will terminate sooner than as set forth in Section 9.2 above if the Licensee shall
at any time default under any obligation under this Agreement relating to a failure to make any Report, pay any Royalty payments, or
permit the inspection of its books and records upon proper notice as herein-above required, and such default is not cured within ten
(10) days after written notice to Licensee specifying the nature of the default.


 


9.4.
Effects of Termination. If this Agreement is terminated, cancelled, or expires for any cause or reason whatsoever:


 


9.4.1.
Nothing herein shall relieve Licensor or Licensee of any obligations or liability accrued hereunder prior to such termination, nor rescind
or give rise to any rights or rescind anything done or any payments made or other consideration given hereunder prior to the effective
time of such termination and shall not effect in any manner the rights of either party arising out of the Agreement prior to such termination;
and


 


9.4.2.
After the effective date of the termination, Licensee will provide Licensor with a report for all Royalties due as of the date of termination
and a written inventory of all Licensed Products in process of manufacture or in stock. Provided Licensee is not in default under this
Agreement, Licensee may sell any such remaining Licensed Product inventory within ninety (90) days following such termination provided
all Royalties are paid thereon within five (5) business days of all such sales. Otherwise all such inventory shall be delivered to Licensor
at no charge; and


 


9.4.3.
The License shall be immediately and automatically revoked without notice. Except as expressly permitted by Section 9.4.2, Licensee shall
immediately cease all use of the Licensed Product, and all rights and privileges granted to Licensee hereunder shall immediately and
automatically revert to Licensor. Licensee shall also immediately return to Licensor all Confidential Information in Licensee’s
possession, custody, or control.


 




    	9



     


    

 


ARTICLE
10 - OBLIGATIONS AND DUTIES OF THE LICENSOR


 


10.1.
Ownership/Conveyance Warranty. Licensor warrants to the Licensee that it is the sole owner of all Patents and Intellectual Property
rights being licensed hereunder.


 


10.2.
No Interfering Rights Warranty. Licensor is not aware of any conflicting third party property rights, including blocking patents,
copyrights, or any other rights of third parties, that may interfere with any of Licensee’s activities under this Agreement or
diminish the rights conveyed to Licensee by this Agreement. However, Licensor makes no warranties that: (a) the Technology or disclosures
in the Patents are accurate, correct, defect-free, or error free, or that the use of the foregoing information is adequate for the production
or use of the Licensed Products or that the technical information is complete; (b) the use of the License, the Licensed Product or any
activities under this Agreement does not infringe third parties’ rights or does not cause damages to third parties; or (c) any
of the Patents now issued or later issued are valid or enforceable.


 


ARTICLE
11 - COMMUNICATIONS AND NOTICES


 


11.1.
Mode and Manner. Any payment, notice, or other communication required or permitted to be made or given to either party hereto
pursuant to this Agreement will be in writing and will be sufficiently made or given on the date of service if sent to such party by
overnight delivery or by certified or registered mail, postage pre-paid, addressed to it at its address set forth above or to such other
address as it designates by written notice delivered to the other party.


 


ARTICLE
12 - OWNERSHIP OF IMPROVEMENTS


 


12.1.
Licensor Improvements. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
by Licensor or its employees, all inventions entitled to any patent or patents maturing therefrom will be owned by Licensor (a “Licensor
Invention”).


 


12.2.
Joint Invention Rights. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
under which the Licensor and the Licensee or any of their respective employees may be a joint inventor, all inventions entitled to any
patent or patents maturing therefrom will be owned solely by Licensor, and Licensee hereby irrevocably and unconditionally assigns to
Licensor all rights, title, and interest therein worldwide and to any and all Patents thereon.


 


12.3.
Licensee Improvements. In the event that any Improvements are conceived or reduced to practice during the course of this Agreement
solely by Licensee or its employees, agents, or contractors, all inventions entitled to any patent or patents maturing therefrom will
be owned solely and exclusively by Licensee (a “Licensee Invention”). Licensee shall promptly disclose to Licensor
each Licensee Invention and shall offer Licensor a license to use the same and the parties shall negotiate in good faith.


 


ARTICLE
13 – CONFIDENTIALITY


 


13.1.
Confidential Information. For purposes of this Agreement the term “Confidential Information” includes any information
disclosed by one party to another under this Agreement that is not publicly or generally known including, but not limited to, ideas,
inventions, discoveries, improvements, algorithms, formulas, computer programs, Technology, Improvements, the contents of unpublished
patent applications, product plans, products, product updates and upgrades, services, pricing information, developments, processes, designs,
drawings, engineering, development information, trial and clinic tests, research and development, customer lists, customer information,
marketing, advertising, business and marketing plans, business and financial information, whether protectable under applicable patent
or copyright law or otherwise. Licensee represents, acknowledges, and agrees that the Technology contains highly valuable and proprietary
trade secrets of the Licensor and that Licensee receives a competitive advantage in the Territory marketplace by receiving a license
to these trade secrets from Licensor on the terms and conditions set forth in this Agreement.


 




    	10



     


    

 


13.2.
Restrictions on Confidential Information. During the term of this Agreement and thereafter until such time as that portion of
the Confidential Information no longer qualifies for protection as trade secrets or confidential or proprietary business information
under all applicable laws, each party will maintain the other party’s Confidential Information in strict confidence and will not
directly or indirectly use the Confidential Information except during the term of this Agreement in connection with each party’s
performance under this Agreement, and neither party will disclose the Confidential Information to any third parties. Upon the termination
or expiration of this Agreement or at the request of either party at any time, each party will return the other party’s Confidential
Information to that party.


 


13.3.
Exclusions. The confidentiality obligation in Section 13.2 shall lapse if Confidential Information: (i) becomes a part of the
public domain without breach of this Agreement by the receiving party; or (ii) is legitimately obtained by the receiving party without
a commitment of confidentiality from a third party. Either party may provide Confidential Information to an authorized body pursuant
to judicial action or government regulations, provided that the party required to disclose Confidential Information shall promptly notify
the other party in writing, who may seek to obtain suitable protective orders to maintain the confidentiality of Confidential Information
before the disclosing party actually makes such disclosure.


 


ARTICLE
14 - CONSENT AND COOPERATION


 


14.1.
Consent. Any party who is required to give consent under this Agreement will not unreasonably withhold it. Each party will execute
any instruments reasonably necessary to implement the provisions of this Agreement.


 


14.2.
Non-Assignability. The parties agree that this Agreement imposes personal obligations upon Licensee and, without Licensor’s
prior written consent, which consent shall not be unreasonably withheld, Licensee will not assign or transfer any rights under this Agreement,
whether by agreement, merger, reorganization, or in connection with the sale of all or substantially all of the assets or equity interest
in Licensee, or by operation of law or otherwise. Any attempted assignment in breach of this Section 14.2 shall be void and of no force
or effect.


 


14.3.
Buy-Out. In the event that a third party acquires Licensor by agreement, merger, reorganization, or in connection with the sale
of all or substantially all of the assets or equity interest in Licensor, or by operation of law or otherwise, all Intellectual Property
rights held by Licensor and subject to the License shall be transferred to Licensee for reasonable consideration as part of such transaction.


 




    	11



     


    

 


14.4.
Benefits and Burdens. This Agreement and each and every covenant, term, and condition herein is binding upon and inures to the
benefit of the parties hereto and their respective successors and permitted assigns. This Agreement is binding upon any third parties
that acquire all ownership or control of one of the parties hereto through a transfer and ownership interest or as a part of the sale
of all or substantially all of one of the party’s assets.


 


14.5.
No Benefit to Others. The representations, warranties, covenants, and agreements contained in this Agreement are for the sole
benefit of the parties hereto and their heirs, executors, administrators, legal representatives, successors, and permitted assigns, and
they will not be construed as conferring any rights on any other persons. The parties agree there are no express or intended third party
beneficiaries of this Agreement.


 


14.6.
Cooperation. Licensee shall, during the Term of this Agreement and following the termination, cancellation, or expiration thereof,
execute such documents and provide such cooperation as Licensor may reasonably request from time to time to ensure that all right, title,
and interest in and to the Intellectual Property reside with Licensor.


 


ARTICLE
15 - GOVERNING LAW


 


15.1.
Governing Law. This Agreement shall be governed by, and interpreted under, the laws of the State of Delaware applicable to contracts
made and to be performed therein, without giving effect to the principles of conflicts of law. Except in respect to an action commenced
by a third party in another jurisdiction and actions under Section 6.4.3, the parties hereto hereby agree that any legal suit action,
or proceeding arising out of or relating to this Agreement must be exclusively instituted in a federal or state court in Hillsborough
County, Tampa, Florida, and the parties hereto hereby irrevocably submit to the jurisdiction of any such court and waive any objection
to the laying of venue in, jurisdiction over their person in, or the inconvenience of, such forum.


 


15.2.
Venue for Equitable Relief. Notwithstanding Section 15.1 above, in the event Licensee is in breach of any obligation under this
Agreement, Licensor shall have the right to institute suit in any state or federal court of competent jurisdiction located within the
Territory to obtain equitable, emergency, or provisional relief under this Agreement including, without limitation, a temporary or preliminary
injunction or specific performance and the parties agree that such court shall retain jurisdiction throughout the entirety of the proceedings
through entry of final judgment or adjudication of all issues.


 


ARTICLE
16 - ADDITIONAL TERMS


 


16.1.
Counterparts and Translations. This Agreement may be prepared in two identical and original counterparts. If a counterpart shall
be prepared in a language other than English, then the English language version shall control and the non-English counterpart shall be
for convenience only and shall not affect the performance or interpretation of the Agreement. Likewise, the exchange of a fully executed
Agreement by electronic transmission (whether by separately executed counterparts or otherwise) shall be fully binding on the parties
with respect to the terms and conditions of the Agreement.


 


16.2.
Headings, Persons, and Plurals. All section headings contained in this Agreement are for convenience of reference only, do not
form a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. Words used herein, regardless
of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other
gender, masculine, feminine, or neuter, as the context requires. Any reference to a “person” herein shall include an individual,
firm, corporation, partnership, trust, governmental authority or body, association, unincorporated organization, or any other entity.


 




    	12



     


    

 


16.3.
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and
valid under applicable law. However, if any provision of this Agreement or the application of any provision to any party or circumstance
shall be prohibited by or invalid under applicable law, such provision shall be reduced to such scope as is reasonable and enforceable
if possible. Otherwise, such provision shall be ineffective to the extent of such prohibition or invalidity without it invalidating the
remainder of the provisions of this Agreement or the application of the provision to the other parties or other circumstances.


 


16.4.
Attorneys’ Fees. In connection with any legal, arbitration, and/or other proceedings arising out of or relating to this
Agreement, including appeal and enforcement, the prevailing party shall be entitled to recover its reasonable attorneys’ fees,
costs, and expenses from the other party.


 


16.5.
No Other Rights. Except as otherwise provided herein by the License, no license or other rights, express or implied, are granted
to either party. The relationship of Licensor to Licensee is that of an independent contractor and neither Licensee nor its agents or
employees shall be considered employees of Licensor. This Agreement does not constitute and shall not be construed as constituting a
partnership or joint venture or grant of a franchise between Licensor and Licensee. This Agreement shall not be construed as authority
for either party to act for the other party in any agency or other capacity or to make commitments of any kind for the account of or
on behalf of the other, except to the extent and for the purposes provided herein.


 


16.6.
Integration. This Agreement and any attached exhibits constitute the entire and only agreement between the parties regarding the
subject matter of hereof, and all prior negotiations, representations, agreements, and understandings are superseded hereby. No agreements
altering or supplementing the terms hereof may be made except by a written document signed by both parties. No terms or provisions in
any subsequent shipping documents, bills of lading, purchase orders, or other similar documents that are materially different from these
terms and conditions shall be binding upon either party unless evidenced in writing by a duly authorized officer of each party. Such
terms or provisions not in compliance with this section shall be of no force or effect.


 


16.7.
Equitable Relief. The parties stipulate that a breach of Article 13 or of Sections 12.2 or 12.3 above will cause immediate and
irreparable harm and significant injury, for which there is no adequate remedy at law and that Licensor shall be entitled, in addition
to any other rights and remedies it may have, to specific performance and other equitable remedies to restrain any threatened, continuing
or further breach of this Agreement without proof of actual damages sustained by Licensor and without the requirement of posting a bond.
In addition to these equitable remedies, Licensee shall be liable to Licensor for any and all damage to Licensor caused by Licensee’s
breach of Article 13 or of Sections 12.2 or 12.3.


 


16.8.
No Waiver. No waiver shall be effective unless in writing. The failure of any party to enforce a right under this Agreement will
not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved.


 


16.9.
Limitation on Use. Nothing in this Agreement will be construed as conferring upon either party the right to include in any reference
to the other party, anywhere in the world, its trademarks, trade names, service marks, those trademarks and services marks used in connection
with the Licensed Products, or other trade identity without the other party’s prior express written consent.


 


16.10.
Interpretation. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not
apply to the interpretation and construction of this Agreement, and this Agreement shall be construed as having been jointly drafted
by the parties.


 


16.11.
Survival. The provisions of Articles 1, 8, 12, 13, 15, and 16, and Sections 3.5, 3.6, 3.7, 3.8, 4.2, 4.3, 4.4, 4.6, 5.1, 7.1,
7.2, 7.5, 9.4, and 14.6 and all other terms and provisions which by their nature survive the termination, expiration, or cancellation
of this Agreement, shall so survive.


 


[Remainder
of page intentionally left blank; signature page follows]


 




    	13



     


    

 


IN
WITNESS WHEREOF, the Licensor and Licensee have caused this Agreement to be executed by their respective duly authorized officers as
of the date first written above.


 


	 	Licensor:
	 	 
	 	MEDOVEX,
    CORP.,

    a
    Nevada corporation

	 	 
	 	By:	         
	 	Name:	 
	 	Title:	 


 


	 	Licensee:
	 	 
	 	MEDOVEX,
    LLC,

    a
    Delaware limited liability company

	 	 	 
	 	By:	         
	 	Name:	 
	 	Title:	 


 


Signature
Page to Intellectual Property License Agreement


 




    	 



     


    

 


EXHIBIT
“A”


 


	MB
    Ref.	 	STATUS	 	COUNTRY
    NAME	 	TITLE	 	INVENTORS	 	APPLICATION
    NUMBER	 	DATE
    FILED	 	LOCAL
    FILING DATE	 	PUBLICATION
    NO.	 	PUBLICATION
    DATE	 	PATENT
    NUMBER	 	GRANT
    DATE
	1179.10.CN	 	Published	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	2017100570314	 	1/26/17	 	 	 	107049473	 	Aug
    18, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.CNX	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	2017200981285	 	1/26/17	 	 	 	207220874	 	 	 	ZL2017200981285	 	4/13/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.EP	 	Published	 	European
    Patent Office	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	17702236.5	 	1/17/17	 	8/24/18	 	3407810	 	Dec
    5, 2018	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.10.WO	 	Completed	 	PCT	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	PCTUS17013744	 	1/17/17	 	 	 	WO17132004	 	Aug
    3, 2017	 	 	 	 


 




    	Exhibit A-1



     


    

 


	1179.10PR	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Scott M. W. Haufe, Jacob Blank, Adam L. Gullickson, Seth Iverson	 	62/288,638	 	1/29/16	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3	 	Issued	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	14/257,490	 	4/21/14	 	 	 	14
    0324044	 	Oct
    30, 2014	 	9883882	 	2/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.AU	 	Issued	 	Australia	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2014257302	 	4/21/14	 	9/22/15	 	 	 	 	 	2014257302	 	7/30/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.AU2	 	Pending	 	Australia	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2019205969	 	4/21/14	 	7/15/19	 	 	 	 	 	 	 	 


 




    	Exhibit A-2



     


    

 


	1179.3.BR	 	Published	 	Brazil	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	1120150259359	 	4/21/14	 	10/13/15	 	2429	 	Jul
    25, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CA	 	Published	 	Canada	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2938631	 	4/21/14	 	8/3/16	 	2938631	 	Oct
    30, 2014	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CN	 	Issued	 	China	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe	 	2014101674798	 	4/24/14	 	 	 	104116555	 	Oct
    29, 2014	 	104116555	 	1/22/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.CNX	 	Issued	 	China	 	Minimally
    Invasive Surgical Tools for Spinal Facet Therapy To Alleviate Pain And Associated Kits And Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2014202029334	 	4/24/14	 	 	 	204394669	 	 	 	ZL2014202029334	 	6/17/15


 




    	Exhibit A-3



     


    

 


	1179.3.CNX2	 	Issued	 	China	 	Minimally
    Invasive Surgical Tools for Spinal Facet Therapy To Alleviate Pain And Associated Kits And Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2015202423693	 	4/21/15	 	4/21/15	 	 	 	 	 	ZL2015202423693	 	10/28/15
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.EP	 	Published	 	European
    Patent Office	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	14787585.0	 	4/21/14	 	9/22/15	 	2991564	 	Mar
    9, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.HK	 	Issued	 	Hong
    Kong	 	SURGICAL
    TOOLS AND KITS FOR PAIN ALLEVIATING SPINAL JOINT FACET THERAPY	 	Scott
    M. W. Haufe	 	151040272	 	7/19/19	 	 	 	1203342A	 	Oct
    30, 2015	 	1203342B	 	3/20/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.MX	 	Issued	 	Mexico	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	2015014936	 	4/21/14	 	10/23/15	 	 	 	 	 	367291	 	8/13/19


 




    	Exhibit A-4



     


    

 


	1179.3.NZ	 	Issued	 	New
    Zealand	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	712599	 	4/21/14	 	9/22/15	 	 	 	 	 	712599	 	6/26/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3.WO	 	Completed	 	PCT	 	Minimally
    Invasive Methods for Spinal Facet Therapy to Alleviate Pain and Associated Surgical Tools, Kits and Instructional Media	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	PCTUS14034743	 	4/21/14	 	 	 	WO14176141	 	Oct
    30, 2014	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3CT	 	Published	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	15/850,630	 	12/21/17	 	 	 	20180132879	 	May
    17, 2018	 	 	 	 


 




    	Exhibit A-5



     


    

 


	1179.3DV	 	Published	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	15/850,662	 	12/21/17	 	 	 	20180132880	 	May
    17, 2018	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3PR	 	Expired	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET DEBRIDEMENT TO ALLEVIATE PAIN AND ASSOCIATED KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe	 	61/815,416	 	4/24/13	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.3PR2	 	Expired	 	United
    States of America	 	MINIMALLY
    INVASIVE METHODS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND ASSOCIATED SURGICAL TOOLS, KITS AND INSTRUCTIONAL MEDIA	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	61/977,817	 	4/10/14	 	 	 	 	 	 	 	 	 	 


 




    	Exhibit A-6



     


    

 


	1179.4	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	14/810,683	 	7/28/15	 	 	 	16
    0030106	 	Feb
    4, 2016	 	9980771	 	5/29/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.AU	 	Issued	 	Australia	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2015298241	 	7/17/15	 	1/3/17	 	 	 	 	 	2015298241	 	1/9/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.BG	 	Lapsed	 	Bulgaria	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.BR	 	Closed	 	Brazil	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	1120170014696	 	7/17/15	 	1/24/17	 	2448	 	Dec
    5, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.CN	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2015104534515	 	7/29/15	 	 	 	105411666	 	Mar
    23, 2016	 	ZL2015104534515	 	11/5/19


 




    	Exhibit A-7



     


    

 


	1179.4.CNX	 	Issued	 	China	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	201520557413X	 	7/29/15	 	 	 	205181467	 	 	 	ZL201520557413X	 	4/27/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.DE	 	Issued	 	Germany	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.EP	 	Completed	 	European
    Patent Office	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.FR	 	Issued	 	France	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.GB	 	Issued	 	United
    Kingdom	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	15750853.2	 	7/17/15	 	12/30/16	 	3148451	 	Apr
    5, 2017	 	3148451	 	6/6/18


 




    	Exhibit A-8



     


    

 


	1179.4.HK	 	Issued	 	Hong
    Kong	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	161101801	 	7/29/15	 	8/26/16	 	1221888A	 	Jun
    16, 2017	 	HK1221888	 	7/31/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.IN	 	Published	 	India	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	201747002673	 	7/17/15	 	1/24/17	 	212017	 	May
    26, 2017	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.JP	 	Issued	 	Japan	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2016576012	 	7/17/15	 	12/26/16	 	 	 	 	 	6689761	 	4/10/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.JP2	 	Pending	 	Japan	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	2020005550	 	7/17/15	 	1/17/20	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4.NZ	 	Closed	 	New
    Zealand	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	728003	 	7/17/15	 	1/3/17	 	 	 	 	 	 	 	 


 




    	Exhibit A-9



     


    

 


	1179.4.WO	 	Completed	 	PCT	 	Surgical
    Tools for Spinal Facet Therapy to Alleviate Pain and Related Methods	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter, Seth Iverson, Jacob Blank, Arik Zoran	 	PCTUS15040867	 	7/17/15	 	 	 	WO16018643	 	Feb
    4, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4CT	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	15/964,422	 	4/27/18	 	 	 	20180243029	 	Aug
    30, 2018	 	10588688	 	3/17/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4IP	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	15/093,148	 	4/7/16	 	 	 	16
    0213415	 	Jul
    28, 2016	 	10398494	 	9/3/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4IPDV	 	Published	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank	 	16/520,738	 	7/24/19	 	 	 	20190343575	 	Nov
    14, 2019	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4PR	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	62/031,037	 	7/30/14	 	 	 	 	 	 	 	 	 	 


 




    	Exhibit A-10



     


    

 


	1179.4PR2	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Scott
    M. W. Haufe, Adam L. Gullickson, Robert D. Carter	 	62/043,537	 	8/29/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.4PR3	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS FOR SPINAL FACET THERAPY TO ALLEVIATE PAIN AND RELATED METHODS	 	Robert
    D. Carter, Adam L. Gullickson, Scott M. W. Haufe, Seth Iverson, Jacob Blank, Arik Zoran	 	62/135,791	 	3/20/15	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6	 	Issued	 	United
    States of America	 	SURGICAL
    TOOLS WITH POSITIONAL COMPONENTS	 	Scott
    M. W. Haufe, Robert D. Carter	 	15/527,920	 	12/10/15	 	5/18/17	 	20180310975	 	Nov
    1, 2018	 	10595919	 	3/24/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.CN	 	Issued	 	China	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	201580067317X	 	12/10/15	 	6/9/17	 	106999210	 	Aug
    1, 2017	 	ZL201580067317X	 	10/30/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.DE	 	Issued	 	Germany	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.EP	 	Completed	 	European
    Patent Office	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.GB	 	Issued	 	United
    Kingdom	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	15867310.3	 	12/10/15	 	4/14/17	 	3190997	 	Jul
    19, 2017	 	3190997	 	3/11/20
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6.HK	 	Published	 	Hong
    Kong	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	181014903	 	1/31/18	 	 	 	1241681A	 	Jun
    15, 2018	 	 	 	 


 






    	Exhibit A-11



     


    

 


	1179.6.WO	 	Completed	 	PCT	 	Surgical
    Tools with Positional Components	 	Scott
    M. W. Haufe, Robert D. Carter	 	PCTUS15064988	 	12/10/15	 	             	 	WO16094653	 	Jun
    16, 2016	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6PR	 	Expired	 	United
    States of America	 	Surgical
    Tools with Stabilizers	 	Scott
    M. W. Haufe, Robert D. Carter	 	62/091,226	 	12/12/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.6PR2	 	Expired	 	United
    States of America	 	SURGICAL
    TOOLS WITH STABILIZERS	 	Scott
    M. W. Haufe, Robert D. Carter	 	62/093,589	 	12/18/14	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.8	 	Issued	 	United
    States of America	 	COMBINATION
    TISSUE REMOVAL AND CAUTERIZATION INSTRUMENT	 	Scott
    M. W. Haufe	 	12/361,184	 	1/28/09	 	 	 	10
    0191234	 	Jul
    29, 2010	 	8167879	 	5/1/12
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Scott M. W. Haufe, Jacob Blank	 	29/553,207	 	1/29/16	 	 	 	 	 	 	 	D810290	 	2/13/18
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.CN	 	Issued	 	China	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	201630355939X	 	7/29/16	 	 	 	 	 	 	 	ZL201630355939X	 	1/18/17
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0001	 	6/29/16	 	 	 	 	 	 	 	003254515-0001	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM2	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0002	 	6/29/16	 	 	 	 	 	 	 	003254515-0002	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM3	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0003	 	6/29/16	 	 	 	 	 	 	 	003254515-0003	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM4	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0004	 	6/29/16	 	 	 	 	 	 	 	003254515-0004	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DS.EM5	 	Issued	 	European
    Union	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	003254515-0005	 	6/29/16	 	 	 	 	 	 	 	003254515-0005	 	6/29/16
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DSDV	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	29/631,173	 	12/28/17	 	 	 	 	 	 	 	D854150	 	7/16/19
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1179.9DSDV2	 	Issued	 	United
    States of America	 	SURGICAL
    PORTAL DRIVER	 	Robert
    D. Carter, Jacob Blank, Scott M. W. Haufe	 	29/691,589	 	5/17/19	 	 	 	 	 	 	 	D870887	 	12/24/19


 


    	Exhibit A-12



     


    

 


EXHIBIT
“B”


 


Patent
Number (Granted Patents)


 


3148451


3190997


003254515-0001


003254515-0002


003254515-0003


003254515-0004


003254515-0005


 


Patent
Number (Pending)


 


3407810


2991564


 




    	Exhibit B-1